A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Volumn 12, Issue 14 Pt 1, 2006, Pages 4274-4282

  Garland, Linda L ^a   Hidalgo, Manuel ^a   Mendelson, David S ^a   Ryan, David P ^a   Arun, Banu K ^a   Lovalvo, Jennifer L ^a   Eiseman, Irene A ^a   Olson, Stephen C ^a   Lenehan, Peter F ^a   Eder, Joseph P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANERTINIB; DOCETAXEL; MORPHOLINE DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; CHEMICAL MODEL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; MORPHOLINES; NEOPLASMS; NEUTROPENIA; TAXOIDS;

EID: 33846170171     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2507     Document Type: Article

References (0)